The global continuous renal replacement therapy market revenue was around US$ 1.5 billion in 2021 and is estimated to reach US$ 2.8 billion by 2031, growing at a compound annual growth rate (CAGR) of ...

Employment among patients with kidney disease remains low even after dialysis or a transplant, with physical and social ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for investors. Click for my SGMO stock update.

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective means to grow iPS cell-derived kidney progenitor cells, paving the way for ...

Clinical trials suggesting that hemodiafiltration offers a survival benefit over hemodialysis have largely been conducted among the prevalent dialysis population, so investigators examined an incident ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

Is the WaPo journalistically challenged when it comes to science? You decide. An April 6 article in the Washington Post, one ...

[5,6,7] Although the idea of a wearable artificial kidney (WAK) is not new, it is only the advent ... The outcomes of patients on chronic renal replacement therapy remain dismal with respect ...

In all of last year, the FDA handed out only four new exemptions, including one in February 2024 that covered a pediatric cartridge for continuous renal replacement therapy developed by SeaStar ...

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a ...